NWBO vs. LRCX
NWBO (Northwest Biotherapeutics, Inc.) and LRCX (Lam Research Corporation) are both stocks. NWBO operates in Biotechnology (Healthcare), while LRCX operates in Semiconductor Equipment & Materials (Technology). Over the past 10 years, NWBO returned -9.39%/yr vs 43.64%/yr for LRCX. Their 0.05 correlation means their historical movements had little consistent relationship.
Performance
NWBO vs. LRCX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NWBO achieves a -28.31% return, which is significantly lower than LRCX's 71.50% return. Over the past 10 years, NWBO has underperformed LRCX with an annualized return of -9.39%, while LRCX has yielded a comparatively higher 43.64% annualized return.
NWBO
- 1D
- -0.61%
- 1M
- -11.45%
- 6M
- -43.62%
- YTD
- -28.31%
- 1Y
- -35.62%
- 3Y*
- -32.04%
- 5Y*
- -32.84%
- 10Y*
- -9.39%
- ALL TIME*
- -30.38%
LRCX
- 1D
- -1.58%
- 1M
- -16.62%
- 6M
- 25.75%
- YTD
- 71.50%
- 1Y
- 205.74%
- 3Y*
- 61.40%
- 5Y*
- 37.09%
- 10Y*
- 43.64%
- ALL TIME*
- 23.67%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $3.65B | $3.82B | $3.92B | |
| $362.88K | $599.45K | $662.34K |
NWBO vs. LRCX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NWBO Northwest Biotherapeutics, Inc. | -28.31% | -16.74% | -60.81% | -10.64% | 12.07% | -54.10% | 626.19% | 2.19% | -14.38% | -31.05% |
LRCX Lam Research Corporation | 71.50% | 139.16% | -6.84% | 88.63% | -40.72% | 53.66% | 64.18% | 119.33% | -24.40% | 76.21% |
Correlation
The correlation between NWBO and LRCX is -0.04, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | -0.04 |
Correlation (3Y) Balances recent behavior with more history. | -0.02 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.00 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.03 |
Correlation (All Time) Calculated using the full available price history since Dec 14, 2001 | 0.05 |
Fundamentals
NWBO:
$266.22M
LRCX:
$366.44B
NWBO:
-$0.06
LRCX:
$5.75
NWBO:
261.15
LRCX:
15.93
NWBO:
$937.00K
LRCX:
$23.23B
NWBO:
$416.00K
LRCX:
$11.73B
NWBO:
-$79.62M
LRCX:
$8.70B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NWBO vs. LRCX — Risk / Return Rank
NWBO
LRCX
NWBO vs. LRCX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Northwest Biotherapeutics, Inc. (NWBO) and Lam Research Corporation (LRCX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NWBO | LRCX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.87 | ||
| Sortino ratioReturn per unit of downside risk | -3.78 | ||
| Omega ratioGain probability vs. loss probability | 0.95 | 1.42 | -0.47 |
| Calmar ratioReturn relative to maximum drawdown | -0.63 | 5.08 | -5.71 |
| Martin ratioReturn relative to average drawdown | -1.19 | 21.44 | -22.63 |
Loading charts...
Drawdowns
NWBO vs. LRCX - Drawdown Comparison
The maximum NWBO drawdown since its inception was -99.99%, which is greater than LRCX's maximum drawdown of -87.90%. Use the drawdown chart below to compare losses from any high point for NWBO and LRCX.
Loading charts...
Drawdown Indicators
| NWBO | LRCX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.99% | -87.90% | -12.09% |
Max Drawdown (1Y)Largest decline over 1 year | -52.03% | -41.76% | -10.27% |
Max Drawdown (3Y)Largest decline over 3 years | -85.24% | -47.10% | -38.14% |
Max Drawdown (5Y)Largest decline over 5 years | -91.96% | -56.39% | -35.57% |
Max Drawdown (10Y)Largest decline over 10 years | -93.33% | -56.39% | -36.94% |
Current DrawdownCurrent decline from peak | -99.99% | -32.38% | -67.61% |
Average DrawdownAverage peak-to-trough decline | -97.16% | -28.13% | -69.03% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 27.64% | 9.87% | +17.77% |
Volatility
NWBO vs. LRCX - Volatility Comparison
The current volatility for Northwest Biotherapeutics, Inc. (NWBO) is 17.38%, while Lam Research Corporation (LRCX) has a volatility of 27.34%. This indicates that NWBO experiences smaller price fluctuations and is considered to be less risky than LRCX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NWBO | LRCX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.38% | 27.34% | -9.96% |
Volatility (6M)Calculated over the trailing 6-month period | 38.84% | 52.39% | -13.55% |
Volatility (1Y)Calculated over the trailing 1-year period | 66.37% | 63.10% | +3.27% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 82.08% | 48.97% | +33.11% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 92.64% | 46.20% | +46.44% |
Dividends
NWBO vs. LRCX - Dividend Comparison
NWBO has not paid dividends to shareholders, while LRCX's dividend yield for the trailing twelve months is around 0.35%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LRCX Lam Research Corporation | 0.35% | 0.57% | 1.19% | 0.95% | 1.53% | 0.78% | 1.04% | 1.54% | 2.79% | 1.01% | 1.28% | 1.36% |
NWBO Northwest Biotherapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
NWBO vs. LRCX - Financials Comparison
This section allows you to compare key financial metrics between Northwest Biotherapeutics, Inc. and Lam Research Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
NWBO and LRCX have a correlation of -0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LRCX has higher volatility (27.34%) compared to NWBO (17.38%). In terms of maximum drawdown, NWBO dropped -99.99% vs LRCX's -87.90%.
LRCX currently has the higher Sharpe Ratio (3.37 vs -0.50), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NWBO and LRCX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer